NanoViricides Retains a Consulting Firm to Expedite First FluCide™ Human Trials in Australia
07:00 EDT 23 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
NanoViricides, Inc. (OTC BB: NNVC)
(the "Company") announced today that it has retained Australian
Biologics Pty. Ltd., a regulatory affairs consulting firm, to coordinate
the regulatory review and approval to conduct the first ...
Other Sources for this Article
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
More From BioPortfolio on "NanoViricides Retains a Consulting Firm to Expedite First FluCide™ Human Trials in Australia"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
